10-Q: HeartBeam Inc. Reports Third Quarter 2024 Results, Faces Going Concern Uncertainty

HeartBeam Inc.'s Q3 2024 report reveals increased R&D spending, a net loss, and concerns about the company's ability to continue as a going concern without additional funding.

Summary

• HeartBeam Inc. reported a net loss of $4.979 million for the three months ended September 30, 2024, and a net loss of $14.541 million for the nine months ended September 30, 2024.
• The company's research and development expenses increased significantly, rising by 78% in the third quarter and 71% over the nine-month period compared to the same periods in 2023.
• General and administrative expenses also saw a slight increase of 3% in the third quarter and 6% over the nine-month period.
• As of September 30, 2024, HeartBeam had $5.8 million in cash and cash equivalents, which management believes is insufficient to fund operations for the next twelve months.
• The company is actively seeking additional capital through equity and debt financings, as well as strategic relationships.
• HeartBeam is awaiting FDA clearance for its initial product, a patient-held VECG device, and plans to submit a second 510(k) application for its 12L ECG synthesis software.
• The company completed patient enrollment in its VALID-ECG study, which is designed to demonstrate the equivalence of its synthesized 12L ECG to a standard 12L ECG.
• HeartBeam has 17 issued patents worldwide and is developing AI algorithms to enhance its products' diagnostic capabilities.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses and going concern issues, which are major negatives. While there are positive developments in technology and FDA progress, the financial risks overshadow these, resulting in a low sentiment score.

Positives

• HeartBeam completed patient enrollment in the VALID-ECG study, a key step towards FDA clearance of its 12L ECG synthesis software.
• The company has made progress in its AI program, including presentations at two prestigious Electrophysiology conferences.
• HeartBeam has been granted two new U.S. patents, bringing its total to 17 issued patents worldwide.
• The company is engaged in productive discussions with the FDA to finalize the clearance of its initial product.
• HeartBeam has appointed a new CFO and Chief AI Scientist, strengthening its leadership team.
• The company has an At-The-Market offering with $16.9 million available for issuance.

Negatives

• HeartBeam has incurred significant net losses, with a loss of $14.541 million for the nine months ended September 30, 2024.
• The company's cash balance of $5.8 million is deemed insufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• The company has not yet received FDA clearance for its initial product, and there is no guarantee that it will be cleared.
• The company expects no material commercial revenue in 2024.
• The company has identified material weaknesses in its internal controls.

Risks

• HeartBeam's ability to continue as a going concern is dependent on raising additional capital.
• The company faces risks associated with regulatory approvals, particularly from the FDA.
• There is no guarantee that the company's products will be commercially successful.
• The company faces competition from larger companies and other technology companies.
• The company has identified material weaknesses in its internal controls which could impact financial reporting.

Future Outlook

HeartBeam expects to continue its R&D efforts, pursue FDA clearance for its products, and seek additional funding to support its operations. The company anticipates its Early Access Program for the HeartBeam System will occur in coming months. The company does not anticipate that the HeartBeam System clearance will generate significant revenue before the 12L clearance.

Management Comments

• Management believes the continued achievement of these milestones will provide the Company the ability to raise additional capital.
• Management believes that, when combined with our Products, HeartBeams AI will provide additional value to patients and physicians.
• The company is encouraged by early discussions with industry players and their interest in our technology.

Industry Context

HeartBeam is operating in the rapidly growing field of ambulatory cardiac health monitoring, competing with traditional hospital-based ECG systems and other ambulatory monitoring solutions. The company's VECG technology and AI capabilities position it to potentially disrupt the market with more accurate and convenient diagnostic tools.

Comparison to Industry Standards

• HeartBeam's technology aims to provide diagnostic capabilities equal to or superior to traditional hospital-based 12L ECG systems, as demonstrated in early studies.
• The company's VECG technology is designed to be more accurate than existing ambulatory monitoring solutions, particularly for high-risk Coronary Artery Disease (CAD) patients.
• The company's AI program is focused on developing algorithms to detect various cardiac arrhythmias, which is a common area of focus for companies in the digital health space.
• The company's approach to synthesizing a 12L ECG from a 3 lead system is a novel approach that could provide a competitive advantage.
• The company's focus on a patient-held device is in line with the trend towards more convenient and accessible healthcare solutions.

Management Changes

Related Party Transactions

• The company obtained accounting services from CTRLCFO, a firm in which a prior executive of the Company had significant influence until February 1, 2024.
• The company entered into a consulting agreement with one of the independent Board of Directors to provide business development consulting services.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional capital.
• Employees may be impacted by the company's financial instability and potential restructuring.
• Customers and healthcare providers may benefit from the company's innovative technology if it receives FDA clearance and becomes commercially available.
• Suppliers and creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• HeartBeam will continue to work towards securing FDA clearance for its initial product.
• The company plans to submit a second 510(k) application for its 12L ECG synthesis software.
• HeartBeam will continue to analyze data from the VALID-ECG study.
• The company will continue to develop its AI algorithms.
• HeartBeam will seek additional funding to support its operations.

Key Dates

Keywords

HeartBeam, VECG, ECG, FDA, 510(k), AI, cardiac monitoring, telehealth, arrhythmia, clinical trial, patents, going concern